Precision medicine , “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person,” might be pharma’s next big bet, but at what cost, and are stakeholders prepared to pay? It goes without saying that
The biopharmaceutical industry is entering its modular era. Drug development no longer operates with singular, siloed breakthroughs, but rather thrives on systems that are reused, reconfigured, and simulated. From plug-and-play manufacturing redefining flexibility to digital twins transforming
Predicting how a biotherapeutic will behave in humans is a critical step in drug design —but it's far from straightforward. While nonclinical models can help foresee certain negative effects, they often fall short when it comes to immunotoxicity and other immune-related reactions. With the growing
Technology and science are constantly evolving and advancing, and with them, the world of drug development is also changing. Using AI and CRISPR for gene editing and bioprinting human-like tissues are just some examples of innovations that are set to change how life-saving therapies are developed.
The biopharmaceutical industry is undergoing rapid transformation due to the rising popularity of cell and gene therapy for various cancer conditions, some uncommon diseases, and degenerative conditions, as traditional drugs and biological products show limited success. The field is now moving to
The biotech industry in particular will experience high levels of uncertainty and changes in 2025. Emerging biotech companies are facing significant challenges due to new technologies, intense global competition, and changes in the market. Next year, 2025, may be tough for startups as they
